Norstella Launches Atlas Patient Analytics for Real-World Data Cohort Building

NEW YORK, Sept. 29, 2026 /CourierPR/ -- Norstella, a global biopharma commercial intelligence and data company, has launched a new agentic platform for real-world data, marking a significant advancement in how biopharma teams can access and utilize patient data. The platform, built on Norstella's structured and unstructured real-world data foundation, includes its first agent, Atlas Patient Analytics, which aims to revolutionize the way teams build and verify patient cohorts.

Atlas Patient Analytics is designed to streamline the process of cohort building, a critical step in the development of breakthrough therapies.

The platform offers several key features, including a conversational cohort-building process, where teams can describe the population they need in plain language and refine the definition through dialogue. This approach ensures that the inclusion and exclusion criteria, code sets, and query logic behind a supported cohort are visible and can be verified and rerun.

The platform is built on NorstellaLinQ, which spans over 85 million EHR-covered lives, 350 million unique patients, and 3 billion clinical notes, with roughly seven years of linked patient history. It is designed for teams that already license Norstella real-world data, making the data faster and easier to use, reuse, and expand. Atlas Patient Analytics also offers the ability to bring your own code lists, ensuring that the cohort definition can be tailored to specific criteria.

Norstella's new agentic platform is part of a broader strategy to provide biopharma teams with advanced tools to enhance their decision-making processes. The company plans to bring several additional agents to market across the platform, each purpose-built for specific biopharma teams and use cases. Atlas Patient Analytics is the first of these agents, with others expected to follow before the end of the year.

The launch of Atlas Patient Analytics underscores Norstella's commitment to leveraging AI to improve the efficiency and accuracy of real-world data analysis. The platform is designed to address the limitations of current tools, which often provide answers without the transparency and reproducibility needed for robust research and development. By offering a defensible, reproducible cohort, Atlas Patient Analytics aims to bridge this gap, ensuring that biopharma teams can build and verify patient cohorts with greater ease and confidence.